Research letterFailure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease
Section snippets
Acknowledgments
The authors acknowledge Prometheus Biosciences for performing the drug assays and RiskImmune testing at no cost. Data and analytic methods underlying this article will be shared on reasonable request to the corresponding author.
CRediT Authorship Contributions
Elizabeth A. Spencer, MD (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Lead). Jordan Stachelski,
References (8)
Gastroenterology
(2020)Lancet Gastroenterol Hepatol
(2019)Gastroenterology
(2020)J Immunol Methods
(2012)
Cited by (0)
Conflicts of interest These authors disclose the following: Jordan Stachelski and Thierry Dervieux are employees of Prometheus Laboratories. Marla C. Dubinsky is a consultant for Prometheus Laboratories, Janssen, Abbvie, Takeda, Celgene, Gilead, UCB, Pfizer, Arena, and Eli Lilly and co-founder of Mi Test Health and Trellus Health. The remaining author discloses no conflicts.
Funding None.